Pillar Biosciences Expands NGS Partnership with Illumina
Pillar Biosciences, known for its innovation in Decision Medicine™, has recently expanded its collaboration with Illumina. This strategic partnership aims to integrate Pillar's next-generation sequencing (NGS) technology more robustly into Illumina's product offerings. This development marks a significant step forward in enhancing precision therapies for cancer patients.
New Tools for Oncology Panels
Under this partnership, a wider range of Pillar's oncoReveal™ NGS panels will now be directly available through Illumina. The recent launch of the MiSeq™ i100 Series has set an exciting stage for these advancements. Customers can soon access several of Pillar's oncology panels as part of validated libraries that are optimized for cutting-edge sequencing platforms. This move not only broadens the oncology panel portfolio but also aids researchers and clinicians in liquid biopsy applications.
Detailed Overview of Available Panels
The expanded oncology panels from Pillar Biosciences will include:
Liquid Biopsy Tumor Profiling
- oncoReveal™ Core LBx
- oncoReveal™ Essential LBx
- oncoReveal™ Fusion LBx
Solid Tumor Profiling
- oncoReveal™ Multicancer RNA Fusion (18-Driver gene RNA panel)
- oncoReveal™ Solid Tumor v2 (48-gene DNA panel)
Additional panels that leverage the newly launched Illumina MiSeq i100 Series encompass:
- oncoReveal Essential MPN
- oncoReveal Myeloid
- oncoReveal Multi-Cancer with CNV and Fusion Panel
- oncoReveal BRCA1 & BRCA2 plus CNV Panel
Industry Leaders Speak Out
Angela Ryan, Vice President of Product Management at Illumina, expressed enthusiasm for this partnership, emphasizing Illumina's dedication to offering a complete workflow solution for customers. She stated, "We are pleased to bring more oncology assays from Pillar Biosciences into our product lineup." This collaborative endeavor showcases a commitment to accelerating innovation in genomic profiling and cancer therapy.
Dan Harma, Chief Commercial Officer at Pillar Biosciences, also shared insights into the significance of this partnership, citing the rapid advancements in NGS technologies over the past 18 months. He noted, "By expanding the oncology offering with rapid, high-quality targeted genomic content, we can ensure more customers have a complete suite of NGS solutions to meet their needs." The partnership aims to maximize efficiency in testing processes, demonstrating a shared commitment to enhancing patient care.
About Pillar Biosciences
Pillar Biosciences stands at the forefront of Decision Medicine™, utilizing advanced NGS testing technology to refine the selection of targeted therapies for cancer patients. From tumor profiling through therapy selection to monitoring recurrences, Pillar aims to improve the overall diagnosing process. With proprietary technologies like SLIMamp® and PiVAT®, their testing solutions reduce costs while improving access and efficiency across the globe. Currently, the company boasts over 20 NGS testing kits in various development stages aimed at both IVD and RUO formats.
In conclusion, the expanded partnership between Pillar Biosciences and Illumina is set to deliver significant advancements in oncology. By merging their innovative technologies, they promise to enhance the landscape of NGS solutions, ultimately improving patient outcomes in cancer treatment.
Frequently Asked Questions
What is the focus of the partnership between Pillar Biosciences and Illumina?
The partnership aims to broaden the availability of Pillar's oncology NGS panels, integrating them into Illumina's sequencing platforms for improved cancer therapy.
What types of NGS panels are now available?
The collaboration supports both liquid and solid tumor profiling, featuring various oncoReveal™ panels tailored for specific genetic insights.
How do Pillar's technologies enhance NGS testing?
Pillar's proprietary SLIMamp® and PiVAT® technologies focus on localizing testing processes and reducing diagnostic costs, improving efficiency in cancer diagnostics.
What is Decision Medicine™?
Decision Medicine™ is an approach utilized by Pillar Biosciences that leverages accurate NGS testing to optimize therapy choices, providing personalized care for cancer patients.
How does this partnership impact cancer research?
By increasing the availability of effective NGS solutions, the partnership fosters advancements in cancer research and facilitates greater accessibility to genomic profiling.
